1 / 40

EPO promotes survival of cancer cells

2003. EPO compromised survival In head and neck cancer pt. 2003. EPO compromised survival In breast cancer (>12Hb). BEST. 2003. EPO accelerated breast cancer Progression . BEST. 2006. EPO promoted local relapse Head and Neck Ca, EPOR+. 2000. Tumors produce EPO. Cancer cells express

maree
Download Presentation

EPO promotes survival of cancer cells

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 2003 EPO compromised survival In head and neck cancer pt. 2003 EPO compromised survival In breast cancer (>12Hb). BEST 2003 EPO accelerated breast cancer Progression . BEST 2006 EPO promoted local relapse Head and Neck Ca, EPOR+ 2000 Tumors produce EPO Cancer cells express EPO-R 2001 EPO promotes survival of cancer cells 2002 EPO is a growth factor for cancer cells 2002 EPO promotes cancer angiogenesis 2003 2003 EPO protects cancer cells from apoptosis

  2. 2006

  3. 2006

  4. 2006

  5. 2006 EPO receptors are present at the invasion front of the tumor cells.

  6. 2003 EPO compromised survival In head and neck cancer pt. 2003 EPO compromised survival In breast cancer (>12Hb). BEST 2003 EPO accelerated breast cancer Progression. BEST 2006 2006 EPO promoted local relapse Head and Neck Ca, EPOR+ Cervix Ca pt. with EPOR+ have poorer survival and more LVI 2000 Tumors produce EPO Cancer cells express EPO-R 2001 EPO promotes survival of cancer cells 2002 EPO is a growth factor for cancer cells 2002 EPO promotes cancer angiogenesis 2003 2003 EPO protects cancer cells from apoptosis

  7. 2007

  8. 2007 1 DAHANCA study 484 patients Head and Neck cancer Good stratification Placebo EPO

  9. 2007 Overall failure

  10. 2003 EPO compromised survival In head and neck cancer pt. 2003 EPO compromised survival In breast cancer (>12Hb). BEST 2003 EPO accelerated breast cancer Progression. BEST 2006 2006 EPO promoted local relapse Head and Neck Ca, EPOR+ Cervix Ca pt. with EPOR+ have poorer survival and more LVI 2007 DAHANCA: 10% local relapse in EPO treated pt. Trend for worse Survival. 2000 Tumors produce EPO Cancer cells express EPO-R 2001 EPO promotes survival of cancer cells 2002 EPO is a growth factor for cancer cells 2002 EPO promotes cancer angiogenesis 2003 2003 EPO protects cancer cells from apoptosis

  11. 2007

  12. 4.2007

  13. 2 “103 study” 2007 Supportive, patients not on chemotherapy 965 patients EPO vs Placebo

  14. 2007

  15. 2007

  16. 2007

  17. 2003 EPO compromised survival In head and neck cancer pt. 2003 EPO compromised survival In breast cancer (>12Hb).BEST 2003 EPO accelerated breast cancer Progression. BEST 2006 2006 EPO promoted local relapse Head and Neck Ca, EPOR+ Cervix Ca pt. with EPOR+ have poorer survival and more LVI 2007 DAHANCA: 10% local relapse in EPO treated pt. Trend for worse Survival. 2007 Study 103: No reduced transfusion needs In cancer pt. not on chemo. Worse survival. 2000 Tumors produce EPO Cancer cells express EPO-R 2001 EPO promotes survival of cancer cells 2002 EPO is a growth factor for cancer cells 2002 EPO promotes cancer angiogenesis 2003 2003 EPO protects cancer cells from apoptosis

  18. 2007 Canadian study

  19. 2007

  20. 2003 EPO compromised survival In head and neck cancer pt. 2003 EPO compromised survival In breast cancer (>12Hb). BEST 2003 EPO accelerated breast cancer Progression. BEST 2006 2006 EPO promoted local relapse Head and Neck Ca, EPOR+ 2007 Cervix Ca pt. with EPOR+ have poorer survival and more LVI 2007 DAHANCA: 10% local relapse in EPO treated pt. Trend for worse Survival. 2007 Study 103: No reduced transfusion needs In cancer pt. not on chemo. Worse survival. Canadian study: Worse survival, not improved QOL. 2000 Tumors produce EPO Cancer cells express EPO-R 2001 EPO promotes survival of cancer cells 2002 EPO is a growth factor for cancer cells 2002 EPO promotes cancer angiogenesis 2003 2003 EPO protects cancer cells from apoptosis

  21. 2007 3 “145 study”

  22. 2003 EPO compromised survival In head and neck cancer pt. 2003 EPO compromised survival In breast cancer (>12Hb). BEST 2003 EPO accelerated breast cancer Progression. BEST 2006 2006 EPO promoted local relapse Head and Neck Ca, EPOR+ 2007 Cervix Ca pt. with EPOR+ have poorer survival and more LVI 2007 DAHANCA: 10% local relapse in EPO treated pt. Trend for worse Survival. 2007 Study 103: No reduced transfusion needs In cancer pt. not on chemo. Worse survival. Canadian study: Worse survival, not improved QOL. 2000 Tumors produce EPO Cancer cells express EPO-R 2001 EPO promotes survival of cancer cells 2002 EPO is a growth factor for cancer cells 2002 EPO promotes cancer angiogenesis 2003 2003 EPO protects cancer cells from apoptosis 2007 Study 145: No survival compromise Lung patients.

  23. 2007

  24. 2007

  25. 2007 10.5.07

  26. Conclusions 2007 EPO The Illusion of Relativity

  27. 2000 Tumors produce EPO Cancer cells express EPO-R 2001 EPO promotes survival of cancer cells 2002 EPO is a growth factor for cancer cells 2002 EPO promotes cancer angiogenesis 2003 ACTIVITY SAFETY 2003 EPO protects cancer cells from apoptosis 2003 EPO compromised survival In head and neck cancer pt. 2003 EPO compromised survival In breast cancer (>12Hb). BEST 2003 EPO accelerated breast cancer Progression. BEST 2006 EPO promoted local relapse Head and Neck Ca, EPOR+ 2006 Cervix Ca pt. with EPOR+ have poorer survival and more LVI 2007 2007 DAHANCA: 10% local relapse in EPO treated pt. Trend for worse Survival. 2007 Study 103: No reduced transfusion needs In cancer pt. not on chemo. Worse survival. Canadian study: Worse survival, not improved QOL. 2007 Study 145: No survival compromise Lung patients.

  28. Escher: The art of making possible the mathematicly impossible in order to reach the highest level of impossibility. The art of making statistically possible what is clinically irrelevant, leaving the clinician with the highest level of confusion. Than, what is clinically relevant?

  29. EPO

  30. But, would patients will accept participating in such clinical trials????

More Related